Published in Sci Rep on November 15, 2016
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17
Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell (1987) 20.27
RNA-programmed genome editing in human cells. Elife (2013) 14.82
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell (1988) 10.75
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (2015) 4.18
Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science (2015) 2.97
Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat (2009) 2.93
In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science (2015) 2.85
Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol (2012) 2.77
Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat (2009) 2.67
Molecular basis of muscular dystrophies. Muscle Nerve (2000) 2.65
Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun (2015) 2.56
Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem (2014) 2.18
Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res (2012) 2.14
Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res (2014) 1.96
Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports (2014) 1.88
Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther (2013) 1.63
A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell (2016) 1.60
Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle (2011) 1.34
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech (2015) 1.30
Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci (2008) 1.30
The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat (2015) 1.26
Target specificity of the CRISPR-Cas9 system. Quant Biol (2014) 1.23
Adenovirus: from foe to friend. Rev Med Virol (2006) 1.15
Quantifying on- and off-target genome editing. Trends Biotechnol (2015) 1.15
Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve (2013) 1.14
Marginal level dystrophin expression improves clinical outcome in a strain of dystrophin/utrophin double knockout mice. PLoS One (2010) 1.14
CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice. Mol Ther (2015) 1.14
Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J (2013) 1.11
Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Ther (2014) 1.09
The Pathogenesis and Therapy of Muscular Dystrophies. Annu Rev Genomics Hum Genet (2015) 1.08
Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. Ann Hum Genet (2005) 1.08
Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells (2005) 1.06
Genome editing at the crossroads of delivery, specificity, and fidelity. Trends Biotechnol (2015) 1.02
Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther (2014) 1.02
Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci Rep (2014) 0.96
Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells. Mol Ther (2006) 0.96
Recent progress in satellite cell/myoblast engraftment -- relevance for therapy. FEBS J (2013) 0.96
Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene. Acta Myol (2015) 0.91
Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells. Methods (2014) 0.89
Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations. Nucleic Acids Res (2016) 0.86
Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells. J Gene Med (2013) 0.86
Engineered Viruses as Genome Editing Devices. Mol Ther (2015) 0.84
Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity. Biotechnol Bioeng (2008) 0.84
Invited review: Stem cells and muscle diseases: advances in cell therapy strategies. Neuropathol Appl Neurobiol (2015) 0.83
Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database. Orphanet J Rare Dis (2012) 0.82
Advances in genetic therapeutic strategies for Duchenne muscular dystrophy. Exp Physiol (2015) 0.81
Current Progress in Therapeutic Gene Editing for Monogenic Diseases. Mol Ther (2016) 0.78
The emerging role of viral vectors as vehicles for DMD gene editing. Genome Med (2016) 0.76